This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Wachmuth ED, Fritze I, Pfleiderer G. An Aminopeptidase Occurring in Pig Kidney. I. An Improved Method of Preparation. Physical and Enzymic Properties. Biochemistry 1966;5:169–174.WachmuthEDFritzeIPfleidererGAn Aminopeptidase Occurring in Pig Kidney. I. An Improved Method of Preparation. Physical and Enzymic PropertiesBiochemistry19665169174Search in Google Scholar
DiNardo CD, Cortes JE. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opin. Investig. Drugs 2013;23:265–272.DiNardoCDCortesJETosedostat for the treatment of relapsed and refractory acute myeloid leukemiaExpert Opin. Investig. Drugs201323265272Search in Google Scholar
Li Z, Tomlinson ACA, Wong AHM, Zhou D, Desforges M, Talbot PJ, Benlekbir S, Rubinstein JL, Rini JM. The human coronavirus HCoV-229E S-protein structure and receptor binding. eLife 2019;8:art. no. e51230.LiZTomlinsonACAWongAHMZhouDDesforgesMTalbotPJBenlekbirSRubinsteinJLRiniJMThe human coronavirus HCoV-229E S-protein structure and receptor bindingeLife20198art. no. e51230.Search in Google Scholar
Ichinose Y, Genka K, Koike T et al. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J. Natl. Cancer. Inst. 2003;95: 605–610.IchinoseYGenkaKKoikeTRandomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinomaJ. Natl. Cancer. Inst.200395605610Search in Google Scholar
Lee S, Desai P, Edirisinghe B, Pianello S et al. Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. Leuk Lymphoma. 2021;62:498–500.LeeSDesaiPEdirisingheBPianelloSPhase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapyLeuk Lymphoma202162498500Search in Google Scholar
Dennis M, Burnett A, Hills R et al. National Cancer Research Institute (NCRI) acute myeloid leukemia (AML) Working Group. A randomized evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukemia: results of the LI-1 trial. Br. J. Haematol. 2021;194:298–308.DennisMBurnettAHillsRNational Cancer Research Institute (NCRI) acute myeloid leukemia (AML) Working GroupA randomized evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukemia: results of the LI-1 trialBr. J. Haematol.2021194298308Search in Google Scholar
Reid AH, Protheroe A, Attard G, Hayward N et al. A first-in-man phase I and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin. Cancer. Res. 2009;15:4978–4985.ReidAHProtheroeAAttardGHaywardNA first-in-man phase I and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumorsClin. Cancer. Res.20091549784985Search in Google Scholar
Farsa O, Dockal M, Kovacikova J, Benesova, M. Synthesis of 2-{[2-(2-oxo-1-azacycloalkyl)acetamido]phenoxy}acetic acids and their activity as aminopeptidase M inhibitors. J. Serb. Chem. Soc. 2008;73:771–780.FarsaODockalMKovacikovaJBenesovaMSynthesis of 2-{[2-(2-oxo-1-azacycloalkyl)acetamido]phenoxy}acetic acids and their activity as aminopeptidase M inhibitorsJ. Serb. Chem. Soc.200873771780Search in Google Scholar
Farsa O, Sedlakova S, Podlipna J, Maxa J. Aminopeptidase N inhibition could be involved in the anti-angiogenic effect of dobesilates. J. Serb. Chem. Soc. 2014;79:605–612.FarsaOSedlakovaSPodlipnaJMaxaJAminopeptidase N inhibition could be involved in the anti-angiogenic effect of dobesilatesJ. Serb. Chem. Soc.201479605612Search in Google Scholar
Farsa O, Kana J, Macku I et al. Synthesis and aminopeptidase N inhibiting activity of 2-(nitrophenoxymethyl)-[1,3,2] dioxaborolan-2-ols and their open analogs. Acta Pol. Pharm. 2017;74:127–135.FarsaOKanaJMackuISynthesis and aminopeptidase N inhibiting activity of 2-(nitrophenoxymethyl)-[1,3,2] dioxaborolan-2-ols and their open analogsActa Pol. Pharm.201774127135Search in Google Scholar
Farsa O, Haluska M. A single-and multiparametric QSAR study of aminopeptidase N inhibitors. Farmacia 2016;64:283–290.FarsaOHaluskaMA single-and multiparametric QSAR study of aminopeptidase N inhibitorsFarmacia201664283290Search in Google Scholar
Amin SA, Adhikari N, Jha T. Design of Aminopeptidase N Inhibitors as Anti-cancer Agents. J. Med. Chem. 2018;61:6468–6490.AminSAAdhikariNJhaTDesign of Aminopeptidase N Inhibitors as Anti-cancer AgentsJ. Med. Chem.20186164686490Search in Google Scholar
Farsa O, Ballayová V, Žáčková R, Kollar P, Kauerová T, Zubáč P. Aminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment Resistance. Int. J. Mol. Sci. 2022;23:9813.FarsaOBallayováVŽáčkováRKollarPKauerováTZubáčPAminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment ResistanceInt. J. Mol. Sci.2022239813Search in Google Scholar